Novo Nordisk posts teen glycemic win
- Novo Nordisk said on April 23 its phase 3a PIONEER TEENS trial met its main goal, with oral semaglutide beating placebo in youths with type 2 diabetes. - In 132 patients ages 10 to 17, oral semaglutide cut HbA1c by 0.83 percentage points versus placebo at 26 weeks in the randomized study. - Novo plans U.S. and EU pediatric filing in second-half 2026 as it seeks the first oral GLP-1 option for this group. (novonordisk.com)
Type 2 diabetes means the body keeps blood sugar running too high, and doctors track that with HbA1c, a three-month average. Novo Nordisk said April 23 that its oral semaglutide pill lowered HbA1c more than placebo in teenagers. (novonordisk.com) The result came from PIONEER TEENS, a phase 3a trial in 132 children and adolescents ages 10 to 17 with type 2 diabetes. Participants were randomized to oral semaglutide or placebo on top of metformin, basal insulin, or both. (novonordisk.com) (clinicaltrials.gov) At 26 weeks, oral semaglutide reduced HbA1c by 0.83 percentage points versus placebo, meeting the study’s main endpoint. Novo Nordisk said the safety profile was consistent with earlier semaglutide trials. (novonordisk.com) (drugs.com) Semaglutide is a glucagon-like peptide-1, or GLP-1, receptor agonist, a drug class that helps the body release insulin, slows stomach emptying, and reduces appetite. In adults, Novo sells injectable semaglutide as Ozempic and Wegovy and oral semaglutide as Rybelsus. (novonordisk.com 1) (novonordisk.com 2) Novo said PIONEER TEENS is the first clinical trial of an oral GLP-1 receptor agonist in children and adolescents with type 2 diabetes. The company said it plans to file for a pediatric label expansion in the United States and European Union in the second half of 2026. (novonordisk.com) (appliedclinicaltrialsonline.com) The comparator here was placebo, not another active diabetes drug, and patients stayed on background treatment during the study. That matters because the topline release shows improved blood sugar control, but not yet a head-to-head win over rival GLP-1 medicines. (clinicaltrials.gov) (novonordisk.com) Youth-onset type 2 diabetes is less common than adult disease but tends to progress aggressively, with earlier complications and higher long-term risk. Novo framed the trial as addressing an unmet need for patients who need more control than current standard care provides. (novonordisk.com) The next step is regulatory review, not a new set of efficacy claims. If approved, oral semaglutide would give pediatric diabetes patients a pill option in a drug class now dominated by injections. (novonordisk.com)
